Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1–positive advanced cervical cancer: a phase II, single-arm study

OBJECTIVE: We report the efficacy and safety of serplulimab, a novel humanized anti–programmed death-1 antibody, plus nanoparticle albumin-bound (nab)-paclitaxel in previously treated patients with programmed death ligand-1 (PD-L1)–positive advanced cervical cancer. METHODS: Patients diagnosed with...

Descripción completa

Detalles Bibliográficos
Autores principales: An, Jusheng, Li, Xiumin, Wang, Jing, Zhu, Lijing, An, Ruifang, Jiang, Kui, Huang, Yi, Wang, Ke, Li, Guiling, Wang, Chunyan, Yuan, Jianlin, Hou, Xiaoli, Yang, Guiyu, Li, Jing, Wang, Qingyu, Zhu, Jun, Wu, Lingying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161140/
https://www.ncbi.nlm.nih.gov/pubmed/37153587
http://dx.doi.org/10.3389/fimmu.2023.1142256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161140/
https://www.ncbi.nlm.nih.gov/pubmed/37153587
http://dx.doi.org/10.3389/fimmu.2023.1142256

Ejemplares similares